SK1702002A3 - Substituted 1,5-dihydropyrrol-2-on derivatives, method for the preparation thereof, drugs containing said compounds and their use - Google Patents

Substituted 1,5-dihydropyrrol-2-on derivatives, method for the preparation thereof, drugs containing said compounds and their use Download PDF

Info

Publication number: SK1702002A3
Authority: SK; Slovakia
Prior art keywords: dihydropyrrol; substituted; carbon atoms; formula; group
Prior art date: 1999-08-06

Application number

SK170-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Michael Przewosny

Hans-Dietrich Stachel

Hermann Poschenrieder

Original Assignee

Gruenenthal Chemie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-07-25

Publication date

2002-07-02

2000-07-25 Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie

2002-07-02 Publication of SK1702002A3 publication Critical patent/SK1702002A3/sk

Links

CDCHBOQVXIGZHA-UHFFFAOYSA-N 1,2-dihydropyrrol-5-one Chemical class O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 title claims abstract description 65
150000001875 compounds Chemical class 0.000 title claims abstract description 55
239000003814 drug Substances 0.000 title claims abstract description 51
238000000034 method Methods 0.000 title claims abstract description 15
238000002360 preparation method Methods 0.000 title claims abstract description 12
229940079593 drug Drugs 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 claims abstract description 34
125000004432 carbon atom Chemical group C* 0.000 claims description 83
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
125000003118 aryl group Chemical group 0.000 claims description 68
125000002947 alkylene group Chemical group 0.000 claims description 41
125000000217 alkyl group Chemical group 0.000 claims description 39
238000011282 treatment Methods 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 38
239000002585 base Substances 0.000 claims description 36
125000001072 heteroaryl group Chemical group 0.000 claims description 31
208000002193 Pain Diseases 0.000 claims description 19
239000000243 solution Substances 0.000 claims description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 17
125000001424 substituent group Chemical group 0.000 claims description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
-1 alkali metal nitrite Chemical class 0.000 claims description 13
206010021143 Hypoxia Diseases 0.000 claims description 12
208000006011 Stroke Diseases 0.000 claims description 12
206010008118 cerebral infarction Diseases 0.000 claims description 10
238000002425 crystallisation Methods 0.000 claims description 10
230000008025 crystallization Effects 0.000 claims description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
WMOSHIIDGLWLMP-UHFFFAOYSA-N 5-benzylidene-4-hydroxy-3-nitropyrrol-2-one Chemical compound OC1=C([N+]([O-])=O)C(=O)NC1=CC1=CC=CC=C1 WMOSHIIDGLWLMP-UHFFFAOYSA-N 0.000 claims description 8
DZMWMJPNSXOKJV-UHFFFAOYSA-N 5-benzylidene-4-methoxy-3-nitrosopyrrol-2-one Chemical compound COC1=C(N=O)C(=O)NC1=CC1=CC=CC=C1 DZMWMJPNSXOKJV-UHFFFAOYSA-N 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
229910052740 iodine Inorganic materials 0.000 claims description 8
229960000583 acetic acid Drugs 0.000 claims description 7
206010015037 epilepsy Diseases 0.000 claims description 7
235000019441 ethanol Nutrition 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
208000030507 AIDS Diseases 0.000 claims description 6
208000007848 Alcoholism Diseases 0.000 claims description 6
206010002660 Anoxia Diseases 0.000 claims description 6
241000976983 Anoxia Species 0.000 claims description 6
206010048962 Brain oedema Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 6
206010011224 Cough Diseases 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 6
206010012735 Diarrhoea Diseases 0.000 claims description 6
206010013654 Drug abuse Diseases 0.000 claims description 6
208000007882 Gastritis Diseases 0.000 claims description 6
208000028017 Psychotic disease Diseases 0.000 claims description 6
206010046543 Urinary incontinence Diseases 0.000 claims description 6
206010001584 alcohol abuse Diseases 0.000 claims description 6
208000025746 alcohol use disease Diseases 0.000 claims description 6
150000001413 amino acids Chemical class 0.000 claims description 6
230000007953 anoxia Effects 0.000 claims description 6
208000006752 brain edema Diseases 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 6
239000012362 glacial acetic acid Substances 0.000 claims description 6
230000007954 hypoxia Effects 0.000 claims description 6
239000002798 polar solvent Substances 0.000 claims description 6
208000020016 psychiatric disease Diseases 0.000 claims description 6
208000023504 respiratory system disease Diseases 0.000 claims description 6
201000000980 schizophrenia Diseases 0.000 claims description 6
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 6
208000011117 substance-related disease Diseases 0.000 claims description 6
AWSYNTAGAPWTDT-UHFFFAOYSA-N 5-benzylidene-4-hydroxy-3-nitrosopyrrol-2-one Chemical compound OC1=C(N=O)C(=O)NC1=CC1=CC=CC=C1 AWSYNTAGAPWTDT-UHFFFAOYSA-N 0.000 claims description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 5
201000006474 Brain Ischemia Diseases 0.000 claims description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
208000023105 Huntington disease Diseases 0.000 claims description 5
206010020751 Hypersensitivity Diseases 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 5
206010028923 Neonatal asphyxia Diseases 0.000 claims description 5
208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 5
208000000323 Tourette Syndrome Diseases 0.000 claims description 5
208000016620 Tourette disease Diseases 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
208000026106 cerebrovascular disease Diseases 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
201000002491 encephalomyelitis Diseases 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
208000033300 perinatal asphyxia Diseases 0.000 claims description 5
TXXYPSNACSSXIZ-UHFFFAOYSA-N 4-(benzylamino)-5-benzylidene-3-nitropyrrol-2-one Chemical compound C=1C=CC=CC=1C=C1NC(=O)C([N+](=O)[O-])=C1NCC1=CC=CC=C1 TXXYPSNACSSXIZ-UHFFFAOYSA-N 0.000 claims description 4
LQJUPTFJSOOWAB-UHFFFAOYSA-N 4-amino-5-benzylidene-3-nitropyrrol-2-one Chemical compound NC1=C([N+]([O-])=O)C(=O)NC1=CC1=CC=CC=C1 LQJUPTFJSOOWAB-UHFFFAOYSA-N 0.000 claims description 4
TVJQLEGQGLLALE-UHFFFAOYSA-N 4-amino-5-benzylidene-3-nitrosopyrrol-2-one Chemical compound NC1=C(N=O)C(=O)NC1=CC1=CC=CC=C1 TVJQLEGQGLLALE-UHFFFAOYSA-N 0.000 claims description 4
TUEXPJMNNUQGCY-UHFFFAOYSA-N 4-anilino-5-benzylidene-3-nitropyrrol-2-one Chemical compound C=1C=CC=CC=1C=C1NC(=O)C([N+](=O)[O-])=C1NC1=CC=CC=C1 TUEXPJMNNUQGCY-UHFFFAOYSA-N 0.000 claims description 4
NXCRTZKBNABZAK-UHFFFAOYSA-N 4-anilino-5-benzylidene-3-nitrosopyrrol-2-one Chemical compound C=1C=CC=CC=1C=C1NC(=O)C(N=O)=C1NC1=CC=CC=C1 NXCRTZKBNABZAK-UHFFFAOYSA-N 0.000 claims description 4
BGRVLNRSYBTMDR-UHFFFAOYSA-N 5-benzylidene-4-(methylamino)-3-nitropyrrol-2-one Chemical compound CNC1=C([N+]([O-])=O)C(=O)NC1=CC1=CC=CC=C1 BGRVLNRSYBTMDR-UHFFFAOYSA-N 0.000 claims description 4
SGDAVGWPZLGKFK-UHFFFAOYSA-N 5-benzylidene-4-(methylamino)-3-nitrosopyrrol-2-one Chemical compound CNC1=C(N=O)C(=O)NC1=CC1=CC=CC=C1 SGDAVGWPZLGKFK-UHFFFAOYSA-N 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
238000007796 conventional method Methods 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
229930195733 hydrocarbon Natural products 0.000 claims description 4
150000002430 hydrocarbons Chemical class 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
RUXHWBMJNBBYNL-UHFFFAOYSA-N 3-hydroxy-1,2-dihydropyrrol-5-one Chemical compound OC1=CC(=O)NC1 RUXHWBMJNBBYNL-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
208000009205 Tinnitus Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
239000002168 alkylating agent Substances 0.000 claims description 3
229940100198 alkylating agent Drugs 0.000 claims description 3
239000012454 non-polar solvent Substances 0.000 claims description 3
239000012038 nucleophile Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000003586 protic polar solvent Substances 0.000 claims description 3
235000010288 sodium nitrite Nutrition 0.000 claims description 3
231100000886 tinnitus Toxicity 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001350 alkyl halides Chemical class 0.000 claims description 2
230000029936 alkylation Effects 0.000 claims description 2
238000005804 alkylation reaction Methods 0.000 claims description 2
230000000949 anxiolytic effect Effects 0.000 claims description 2
150000001649 bromium compounds Chemical class 0.000 claims description 2
150000001805 chlorine compounds Chemical class 0.000 claims description 2
150000004292 cyclic ethers Chemical class 0.000 claims description 2
150000008050 dialkyl sulfates Chemical class 0.000 claims description 2
239000012948 isocyanate Substances 0.000 claims description 2
150000002513 isocyanates Chemical class 0.000 claims description 2
150000002540 isothiocyanates Chemical class 0.000 claims description 2
150000004707 phenolate Chemical class 0.000 claims description 2
150000003141 primary amines Chemical class 0.000 claims description 2
150000003335 secondary amines Chemical class 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
238000011321 prophylaxis Methods 0.000 claims 2
239000011734 sodium Substances 0.000 claims 2
208000020401 Depressive disease Diseases 0.000 claims 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
OBKZDKFOFPRDHH-UHFFFAOYSA-N acetic acid;n-[5-(ethoxymethylidene)-4-hydroxy-1-methyl-2-oxopyrrol-3-yl]acetamide Chemical compound CC(O)=O.CCOC=C1N(C)C(=O)C(NC(C)=O)=C1O OBKZDKFOFPRDHH-UHFFFAOYSA-N 0.000 claims 1
239000002249 anxiolytic agent Substances 0.000 claims 1
239000000010 aprotic solvent Substances 0.000 claims 1
239000003054 catalyst Substances 0.000 claims 1
150000002170 ethers Chemical class 0.000 claims 1
150000008282 halocarbons Chemical class 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
239000012280 lithium aluminium hydride Substances 0.000 claims 1
239000003880 polar aprotic solvent Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
125000004434 sulfur atom Chemical group 0.000 claims 1
229910052723 transition metal Inorganic materials 0.000 claims 1
150000003624 transition metals Chemical class 0.000 claims 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 30
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 30
238000005160 1H NMR spectroscopy Methods 0.000 description 22
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 18
239000004471 Glycine Substances 0.000 description 15
125000000446 sulfanediyl group Chemical group *S* 0.000 description 15
150000003254 radicals Chemical class 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
238000005684 Liebig rearrangement reaction Methods 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 9
239000008351 acetate buffer Substances 0.000 description 9
230000027455 binding Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
238000003556 assay Methods 0.000 description 8
239000013078 crystal Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 8
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
230000004044 response Effects 0.000 description 6
239000013049 sediment Substances 0.000 description 6
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000003446 ligand Substances 0.000 description 5
210000000287 oocyte Anatomy 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000002285 radioactive effect Effects 0.000 description 5
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
150000005840 aryl radicals Chemical class 0.000 description 4
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000001525 receptor binding assay Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000000094 Chronic Pain Diseases 0.000 description 3
230000003502 anti-nociceptive effect Effects 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
229940005483 opioid analgesics Drugs 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
208000018152 Cerebral disease Diseases 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
230000003040 nociceptive effect Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
238000011002 quantification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
ZYECOAILUNWEAL-NUDFZHEQSA-N (4z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-n-(3-nitrophenyl)-3-oxonaphthalene-2-carboxamide Chemical compound COC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1N\N=C(C1=CC=CC=C1C=1)/C(=O)C=1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 ZYECOAILUNWEAL-NUDFZHEQSA-N 0.000 description 1
XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
QVPYEJCCIPLIDD-UHFFFAOYSA-N 4-(benzylamino)-5-benzylidene-3-nitrosopyrrol-2-one Chemical compound C=1C=CC=CC=1C=C1NC(=O)C(N=O)=C1NCC1=CC=CC=C1 QVPYEJCCIPLIDD-UHFFFAOYSA-N 0.000 description 1
WJKYZBBQSRRHNU-UHFFFAOYSA-N 5-benzylidene-4-hydroxypyrrol-2-one Chemical compound OC1=CC(=O)NC1=CC1=CC=CC=C1 WJKYZBBQSRRHNU-UHFFFAOYSA-N 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
241000269350 Anura Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000220304 Prunus dulcis Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
241001247203 Syngnathidae Species 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000035929 gnawing Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000012402 patch clamp technique Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000026416 response to pain Effects 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000007944 thiolates Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
239000005051 trimethylchlorosilane Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Immunology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)

SK170-2002A 1999-08-06 2000-07-25 Substituted 1,5-dihydropyrrol-2-on derivatives, method for the preparation thereof, drugs containing said compounds and their use SK1702002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19936719A DE19936719A1 (de)	1999-08-06	1999-08-06	Substituierte 1,5-Dihydropyrrol-2-on-Derivate
PCT/EP2000/007100 WO2001010833A1 (de)	1999-08-06	2000-07-25	Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen

Publications (1)

Publication Number	Publication Date
SK1702002A3 true SK1702002A3 (en)	2002-07-02

Family

ID=7917172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK170-2002A SK1702002A3 (en)	1999-08-06	2000-07-25	Substituted 1,5-dihydropyrrol-2-on derivatives, method for the preparation thereof, drugs containing said compounds and their use

Country Status (25)

Country	Link
US (1)	US6642267B2 (pl)
EP (1)	EP1200402B1 (pl)
JP (1)	JP2003506437A (pl)
KR (1)	KR20020025214A (pl)
CN (1)	CN1378532A (pl)
AR (1)	AR028848A1 (pl)
AT (1)	ATE304530T1 (pl)
AU (1)	AU782435B2 (pl)
BR (1)	BR0013311A (pl)
CA (1)	CA2381033A1 (pl)
CO (1)	CO5200758A1 (pl)
CZ (1)	CZ2002441A3 (pl)
DE (2)	DE19936719A1 (pl)
ES (1)	ES2248104T3 (pl)
HK (1)	HK1046405A1 (pl)
HU (1)	HUP0201937A3 (pl)
IL (1)	IL147977A0 (pl)
MX (1)	MXPA02001212A (pl)
NO (1)	NO20020574L (pl)
NZ (1)	NZ516988A (pl)
PE (1)	PE20010402A1 (pl)
PL (1)	PL353854A1 (pl)
SK (1)	SK1702002A3 (pl)
WO (1)	WO2001010833A1 (pl)
ZA (1)	ZA200201788B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1269482C (zh) *	2001-05-18	2006-08-16	威克斯医药有限公司	钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060063802A1 (en)	2004-03-29	2006-03-23	Matthieu Guitton	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en)	2004-03-29	2015-07-07	Auris Medical Ag	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en)	2004-03-29	2012-09-18	Matthieu Guitton	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EP2425846A1 (en) *	2004-12-23	2012-03-07	Voyager Pharmaceutical Corporation	Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
CA2620374C (en) *	2005-09-28	2012-12-11	Thomas Meyer	Pharmaceutical compositions for the treatment of inner ear disorders
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
ATE554085T1 (de)	2006-11-30	2012-05-15	Probiodrug Ag	Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja)	2007-03-01	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
KR20160127181A (ko)	2008-08-12	2016-11-02	진판델 파마슈티컬스 인코포레이티드	질환 위험 인자의 식별 방법
US8846315B2 (en)	2008-08-12	2014-09-30	Zinfandel Pharmaceuticals, Inc.	Disease risk factors and methods of use
PL2475428T3 (pl)	2009-09-11	2015-12-31	Probiodrug Ag	Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es)	2010-03-03	2016-10-13	Probiodrug Ag	Inhibidores de glutaminil ciclasa
MX2012010470A (es)	2010-03-10	2012-10-09	Probiodrug Ag	Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
CN107362165A (zh)	2011-01-10	2017-11-21	金帆德尔制药股份有限公司	用于治疗阿尔茨海默病的方法和药物产品
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR102084185B1 (ko) *	2013-08-29	2020-03-04	주식회사 대웅제약	테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) *	2016-12-06	2020-07-07	Intelligrated Headquarters, Llc	Phased deployment of scalable real time web applications for material handling system
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
WO2025145182A1 (en) *	2023-12-29	2025-07-03	Case Western Reserve University	Selective inhibitors of t cell activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL258360A (pl) *	1960-11-25
DE3434562A1 (de) *	1984-09-20	1986-03-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Verwendung von pyrrothinderivaten
GB2170498A (en) *	1985-02-04	1986-08-06	Ici Plc	Processes for making fungicidal dithiolopyrrolones
GB2173499A (en) *	1985-02-04	1986-10-15	Ici Plc	Fungicidal dithiolopyrrolones
GB9210393D0 (en) *	1992-05-15	1992-07-01	Merck Sharp & Dohme	Therapeutic agents

1999
- 1999-08-06 DE DE19936719A patent/DE19936719A1/de not_active Ceased
2000
- 2000-07-25 SK SK170-2002A patent/SK1702002A3/sk not_active Application Discontinuation
- 2000-07-25 NZ NZ516988A patent/NZ516988A/en unknown
- 2000-07-25 IL IL14797700A patent/IL147977A0/xx unknown
- 2000-07-25 AU AU68279/00A patent/AU782435B2/en not_active Ceased
- 2000-07-25 ES ES00956273T patent/ES2248104T3/es not_active Expired - Lifetime
- 2000-07-25 PL PL00353854A patent/PL353854A1/pl not_active Application Discontinuation
- 2000-07-25 HU HU0201937A patent/HUP0201937A3/hu unknown
- 2000-07-25 DE DE50011178T patent/DE50011178D1/de not_active Expired - Lifetime
- 2000-07-25 HK HK02107776.3A patent/HK1046405A1/zh unknown
- 2000-07-25 CN CN00813944A patent/CN1378532A/zh active Pending
- 2000-07-25 BR BR0013311-6A patent/BR0013311A/pt not_active IP Right Cessation
- 2000-07-25 MX MXPA02001212A patent/MXPA02001212A/es active IP Right Grant
- 2000-07-25 KR KR1020027001608A patent/KR20020025214A/ko not_active Withdrawn
- 2000-07-25 WO PCT/EP2000/007100 patent/WO2001010833A1/de not_active Ceased
- 2000-07-25 CA CA002381033A patent/CA2381033A1/en not_active Abandoned
- 2000-07-25 CZ CZ2002441A patent/CZ2002441A3/cs unknown
- 2000-07-25 AT AT00956273T patent/ATE304530T1/de active
- 2000-07-25 EP EP00956273A patent/EP1200402B1/de not_active Expired - Lifetime
- 2000-07-25 JP JP2001515300A patent/JP2003506437A/ja not_active Withdrawn
- 2000-07-31 AR ARP000103963A patent/AR028848A1/es not_active Application Discontinuation
- 2000-08-01 PE PE2000000761A patent/PE20010402A1/es not_active Application Discontinuation
- 2000-08-03 CO CO00058413A patent/CO5200758A1/es not_active Application Discontinuation
2002
- 2002-02-05 NO NO20020574A patent/NO20020574L/no not_active Application Discontinuation
- 2002-02-06 US US10/066,800 patent/US6642267B2/en not_active Expired - Fee Related
- 2002-03-04 ZA ZA200201788A patent/ZA200201788B/xx unknown

Also Published As

Publication number	Publication date
AU782435B2 (en)	2005-07-28
HUP0201937A2 (en)	2002-10-28
DE50011178D1 (de)	2005-10-20
EP1200402A1 (de)	2002-05-02
PL353854A1 (pl)	2003-12-01
HUP0201937A3 (en)	2002-12-28
ZA200201788B (en)	2003-08-27
ES2248104T3 (es)	2006-03-16
CO5200758A1 (es)	2002-09-27
US6642267B2 (en)	2003-11-04
AR028848A1 (es)	2003-05-28
NO20020574L (no)	2002-03-25
DE19936719A1 (de)	2001-02-15
AU6827900A (en)	2001-03-05
CZ2002441A3 (cs)	2002-05-15
BR0013311A (pt)	2003-01-28
ATE304530T1 (de)	2005-09-15
CA2381033A1 (en)	2001-02-15
CN1378532A (zh)	2002-11-06
IL147977A0 (en)	2002-09-12
JP2003506437A (ja)	2003-02-18
US20020161033A1 (en)	2002-10-31
WO2001010833A1 (de)	2001-02-15
NO20020574D0 (no)	2002-02-05
KR20020025214A (ko)	2002-04-03
NZ516988A (en)	2004-11-26
MXPA02001212A (es)	2002-07-02
EP1200402B1 (de)	2005-09-14
PE20010402A1 (es)	2001-05-05
HK1046405A1 (zh)	2003-01-10

Legal Events

Date	Code	Title	Description
2010-02-08	FC9A	Refused patent application

Publication	Publication Date	Title
US6642267B2 (en)	2003-11-04	Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
US6794388B2 (en)	2004-09-21	Succinic acid salts of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
KR20070024639A (ko)	2007-03-02	아미도 화합물 및 약제로서의 이의 용도
SK1692002A3 (en)	2002-07-02	Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use
AU2007254232A1 (en)	2007-11-29	N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
JP2011500694A (ja)	2011-01-06	置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途
WO2023081858A1 (en)	2023-05-11	Condensed-pyrazine amine derivatives for treating sca3
US20100016375A1 (en)	2010-01-21	1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as cb1 receptor modulator
IL101589A (en)	1996-10-31	1-(pyrido [3,4-b]-1,4-oxazin-4-yl)- 1H-indoles a process for their preparation and their use as medicaments
US7501443B2 (en)	2009-03-10	Flavaxate derivatives as muscarinic receptor antagonists
US7057036B2 (en)	2006-06-06	Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
US20070219216A1 (en)	2007-09-20	1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists
RU2338746C2 (ru)	2008-11-20	Новые диазабициклические арильные производные, содержащие их фармацевтические композиции и их применение
AU2007329807B2 (en)	2013-02-14	1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulator
KR20060014373A (ko)	2006-02-15	무스카린 수용체 길항제로서의 치환된 아자비시클로 헥산유도체